drugset
drugset / Trial / NCT00287885

Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer

NCT00287885 ↗

Phase 1 Completed 18 enrolled Masonic Cancer Center, University of Minnesota
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Docetaxel may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving daily doses of docetaxel may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel in treating patients with refractory or recurrent advanced gynecologic cancer.

Timeline

Start
2004-03
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 2.9 mg/m2 Intravenous
Subject Docetaxel Small molecule 6.4 mg/m2 Intravenous

Indications

cervical cancer endometrial cancer fallopian tube cancer ovarian cancer peritoneum cancer sarcoma vaginal cancer vulva cancer